Antipseudomonal penicillin + β-lactamase inhibitor
Piperacillin with tazobactam
Brand names: Tazocin
Adult dose
Dose: 4.5g IV every 8h (or every 6h in severe sepsis); extended infusion 4h often used
Route: IV
Frequency: q6-8h
Paediatric dose
Dose: 90 mg/kg
Route: IV
Frequency: q8h
Age bands
- 0–1m: 90 mg/kg IV q8h
- 1–216m: 90 mg/kg (max 4.5g) IV q6-8h
Dose adjustments
Renal
Reduce if CrCl <40 mL/min
Paediatric weight-based calculator
Clinical pearls
- Hospital-acquired pneumonia, intra-abdominal sepsis, neutropenic sepsis, complicated UTI
- Cover for Pseudomonas; reduce frequency for renal function
Contraindications
- Penicillin allergy
- Severe β-lactam hypersensitivity
Side effects
- Diarrhoea
- C. difficile infection
- Rash
- Hepatotoxicity
- Cytopenias
- Hypokalaemia
- Acute kidney injury (with vancomycin)
- Seizures (high dose / renal impairment)
Interactions
- Methotrexate
- Warfarin
- Aminoglycosides (compatibility)
- Vancomycin (AKI risk)
Monitoring
- FBC
- U&E
- LFTs
- CRP
Reference: BNFc; BNF; NICE NG139/NG143; UKHSA; https://bnf.nice.org.uk/drugs/piperacillin-with-tazobactam/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Centor/McIsaac Score (Pharyngitis) · Throat Infections
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023